Secondary bone/soft tissue sarcoma in childhood cancer survivors: A nationwide hospital-based case-series study in Japan

Yasushi Ishida, Miho Maeda, Souichi Adachi, Takeshi Rikiishi, Maho Sato, Hiroshi Kawaguchi, Atsushi Manabe, Mika Tokuyama, Hiroki Hori, Jun Okamura, Atsushi Ogawa, Hiroaki Goto, Ryoji Kobayashi, Shinji Yoshinaga, Junichiro Fujimoto, Tatsuo Kuroda

Research output: Contribution to journalArticle

Abstract

Background: Secondary cancer is the most life-Threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-To-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95% confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95% CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine, hematopoietic SCT. Twelve CCSs with secondary sarcoma achieved disease-free survival, while CCSs with hematological cancer or relapsed primary cancer who developed secondary sarcoma had the worst prognoses. Conclusion: The prognoses of CCSs with secondary sarcoma may depend on the primary cancer or prior relapse of primary cancer.

Original languageEnglish
Pages (from-to)806-814
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume48
Issue number9
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Sarcoma
Japan
Bone and Bones
Neoplasms
Retinoblastoma
Osteosarcoma
Confidence Intervals
Primitive Neuroectodermal Tumors
Langerhans Cell Histiocytosis
Ewing's Sarcoma
Rhabdomyosarcoma
Hematopoietic Stem Cell Transplantation
Neurilemmoma
Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proportional Hazards Models
Brain Neoplasms
Disease-Free Survival
Lymphoma

Keywords

  • Bone/soft tissue sarcoma
  • Childhood cancer
  • Late effects
  • Secondary cancer
  • Secondary sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Secondary bone/soft tissue sarcoma in childhood cancer survivors : A nationwide hospital-based case-series study in Japan. / Ishida, Yasushi; Maeda, Miho; Adachi, Souichi; Rikiishi, Takeshi; Sato, Maho; Kawaguchi, Hiroshi; Manabe, Atsushi; Tokuyama, Mika; Hori, Hiroki; Okamura, Jun; Ogawa, Atsushi; Goto, Hiroaki; Kobayashi, Ryoji; Yoshinaga, Shinji; Fujimoto, Junichiro; Kuroda, Tatsuo.

In: Japanese Journal of Clinical Oncology, Vol. 48, No. 9, 01.01.2018, p. 806-814.

Research output: Contribution to journalArticle

Ishida, Y, Maeda, M, Adachi, S, Rikiishi, T, Sato, M, Kawaguchi, H, Manabe, A, Tokuyama, M, Hori, H, Okamura, J, Ogawa, A, Goto, H, Kobayashi, R, Yoshinaga, S, Fujimoto, J & Kuroda, T 2018, 'Secondary bone/soft tissue sarcoma in childhood cancer survivors: A nationwide hospital-based case-series study in Japan', Japanese Journal of Clinical Oncology, vol. 48, no. 9, pp. 806-814. https://doi.org/10.1093/jjco/hyy102
Ishida, Yasushi ; Maeda, Miho ; Adachi, Souichi ; Rikiishi, Takeshi ; Sato, Maho ; Kawaguchi, Hiroshi ; Manabe, Atsushi ; Tokuyama, Mika ; Hori, Hiroki ; Okamura, Jun ; Ogawa, Atsushi ; Goto, Hiroaki ; Kobayashi, Ryoji ; Yoshinaga, Shinji ; Fujimoto, Junichiro ; Kuroda, Tatsuo. / Secondary bone/soft tissue sarcoma in childhood cancer survivors : A nationwide hospital-based case-series study in Japan. In: Japanese Journal of Clinical Oncology. 2018 ; Vol. 48, No. 9. pp. 806-814.
@article{cf030b30911d4bb9af48aac659c8211c,
title = "Secondary bone/soft tissue sarcoma in childhood cancer survivors: A nationwide hospital-based case-series study in Japan",
abstract = "Background: Secondary cancer is the most life-Threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-To-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95{\%} confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95{\%} CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine, hematopoietic SCT. Twelve CCSs with secondary sarcoma achieved disease-free survival, while CCSs with hematological cancer or relapsed primary cancer who developed secondary sarcoma had the worst prognoses. Conclusion: The prognoses of CCSs with secondary sarcoma may depend on the primary cancer or prior relapse of primary cancer.",
keywords = "Bone/soft tissue sarcoma, Childhood cancer, Late effects, Secondary cancer, Secondary sarcoma",
author = "Yasushi Ishida and Miho Maeda and Souichi Adachi and Takeshi Rikiishi and Maho Sato and Hiroshi Kawaguchi and Atsushi Manabe and Mika Tokuyama and Hiroki Hori and Jun Okamura and Atsushi Ogawa and Hiroaki Goto and Ryoji Kobayashi and Shinji Yoshinaga and Junichiro Fujimoto and Tatsuo Kuroda",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/jjco/hyy102",
language = "English",
volume = "48",
pages = "806--814",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Secondary bone/soft tissue sarcoma in childhood cancer survivors

T2 - A nationwide hospital-based case-series study in Japan

AU - Ishida, Yasushi

AU - Maeda, Miho

AU - Adachi, Souichi

AU - Rikiishi, Takeshi

AU - Sato, Maho

AU - Kawaguchi, Hiroshi

AU - Manabe, Atsushi

AU - Tokuyama, Mika

AU - Hori, Hiroki

AU - Okamura, Jun

AU - Ogawa, Atsushi

AU - Goto, Hiroaki

AU - Kobayashi, Ryoji

AU - Yoshinaga, Shinji

AU - Fujimoto, Junichiro

AU - Kuroda, Tatsuo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Secondary cancer is the most life-Threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-To-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95% confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95% CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine, hematopoietic SCT. Twelve CCSs with secondary sarcoma achieved disease-free survival, while CCSs with hematological cancer or relapsed primary cancer who developed secondary sarcoma had the worst prognoses. Conclusion: The prognoses of CCSs with secondary sarcoma may depend on the primary cancer or prior relapse of primary cancer.

AB - Background: Secondary cancer is the most life-Threatening late effect of childhood cancer. We investigated the clinical features of secondary bone/soft tissue sarcoma among childhood cancer survivors (CCSs). Methods: We conducted a retrospective case-series study of 10 069 CCSs newly diagnosed with cancer between 1980 and 2009 across 15 Japanese hospitals. Twenty-one cases of pathologically diagnosed secondary bone/soft tissue sarcoma were selected, and the respective clinical courses were determined using additional questionnaires. Results: The primary cancers included retinoblastoma (n = 7), acute lymphoblastic leukemia (n = 5), lymphoma (n = 5), osteosarcoma (n = 1), rhabdomyosarcoma (n = 1), brain tumor (n = 1) and Langerhans cell histiocytosis (n = 1). The median age at the primary cancer diagnosis was 2.9 years, and the male-To-female ratio was 16:5. The histological classifications of the secondary sarcoma included osteosarcoma (n = 10), malignant peripheral nerve sheath tumor (n = 4), rhabdomyosarcoma (n = 3), Ewing's sarcoma (n = 3) and primitive neuroectodermal tumor (n = 1). The median latency period to the secondary sarcoma was 10.2 years. Significant risk factors for secondary sarcoma in the multivariate Cox regression model included a history of retinoblastoma as the primary cancer (hazard ratio [HR], 20.9; 95% confidence interval [CI], 5.70-76.5) and autologous stem cell transplantation (SCT) (HR, 2.56; 95% CI, 1.08-6.03). Seventeen CCSs with secondary sarcoma underwent radiation, and nine, hematopoietic SCT. Twelve CCSs with secondary sarcoma achieved disease-free survival, while CCSs with hematological cancer or relapsed primary cancer who developed secondary sarcoma had the worst prognoses. Conclusion: The prognoses of CCSs with secondary sarcoma may depend on the primary cancer or prior relapse of primary cancer.

KW - Bone/soft tissue sarcoma

KW - Childhood cancer

KW - Late effects

KW - Secondary cancer

KW - Secondary sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85054075833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054075833&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy102

DO - 10.1093/jjco/hyy102

M3 - Article

C2 - 30053029

AN - SCOPUS:85054075833

VL - 48

SP - 806

EP - 814

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 9

ER -